Commissariat à l’énergie atomique et aux energies alternatives (CEA)

IDMIT (Infectious disease models for innovative therapies) is an infrastructure founded by five major academic institutions in France: CEA, INSERM, ANRS, Université Paris Sud and Institut Pasteur. The CEA is the legal entity coordinator of IDMIT. Bertin Pharma is a partner of CEA-IDMIT and as a CRO in charge of collaborations with the pharmaceutical industry as well as the implementation and management of the quality assurance programme. CEA-IDMIT develops NHP models for immune related disorders and infectious diseases for preclinical evaluation of human vaccines, immunotherapies and anti-microbial treatments. CEA-IDMIT has acquired strong expertise and skills in viral pathogenesis, treatment for prevention (microbicides, pre- and post-exposure prophylaxis) and vaccine immunology using NHP models of human viral infections, particularly through its contribution to the development of the NHP model of human HIV infection and AIDS. IDMIT-teams develop research programs using NHP models of human diseases: Flu, chikungunya virus, dengue virus, yellow fever, Ebola, malaria, Chlamydia infection and tuberculosis.

Within the PERISCOPE project, CEA-IDMIT establishes the baboon model to study Bordetella pertussis infection in young animals and in neonatal baboons to study the efficacy of vaccination in pregnancy. IDMIT will develop technologies for imaging Bordetella pertussis infection, tissue lesions and host responses in live baboons. Additionally, CEA-IDMIT will study in the baboon model the role of mucosal immunity following infection or parenteral or nasal immunization. Critical parameters of maternally-transferred immunity from human immunization studies in pregnancy will be explored by CEA-IDMIT in the baboon neonate Bordetella pertussis challenge model. Furthermore, CEA-IDMIT will share its SOPs with PERISCOPE partners to harmonize the techniques used to assess B and T cell responses in pre-clinical and clinical studies.

Dr Roger Le Grand has been head of the IMVA department since 2015, and formerly of the Department of Immuno-virology (SIV) since 2008. He is the IDMIT chief executive since 2012. His research mainly focuses on non-human primate models of human viral infections. Dr Le Grand’s research group is currently developing NHP models for HIV, HBV, dengue, human influenza, Chikungunya, Chlamydia, Pertussis and new emerging diseases. Dr Le Grand is particularly interested in host-pathogen interactions and the prevention of viral transmission.

Main contact

Photo of Roger Le Grand
Dr Roger Le Grand
Role in the project: IDMIT CEO
Phone: + 33-146548757

Other contacts

Dr Nathalie Dereuddre-Bosquet
Role in the project: Head of IDMIT core facilities
Dr Catherine Chapon
Role in the project: Head of In vivo imaging core facilities
Dr Isabelle Mangeot
Role in the project: Project manager